Enbrel

Product manufactured by A-S Medication Solutions

Application Nr Approved Date Route Status External Links
BLA103795 None Subcutaneous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Enbrel Is A Tumor Necrosis Factor (tnf) Blocker Indicated For The Treatment Of: Rheumatoid Arthritis (ra) ( 1.1 ) Polyarticular Juvenile Idiopathic Arthritis (jia) In Patients Aged 2 Years Or Older ( 1.2 ) Psoriatic Arthritis (psa) ( 1.3 ) Ankylosing Spondylitis (as) ( 1.4 ) Plaque Psoriasis (pso) In Patients 4 Years Or Older ( 1.5 ) 1.1 Rheumatoid Arthritis Enbrel Is Indicated For Reducing Signs And Symptoms, Inducing Major Clinical Response, Inhibiting The Progression Of Structural Damage, And Improving Physical Function In Patients With Moderately To Severely Active Rheumatoid Arthritis (ra). Enbrel Can Be Initiated In Combination With Methotrexate (mtx) Or Used Alone. 1.2 Polyarticular Juvenile Idiopathic Arthritis Enbrel Is Indicated For Reducing Signs And Symptoms Of Moderately To Severely Active Polyarticular Juvenile Idiopathic Arthritis (jia) In Patients Ages 2 And Older. 1.3 Psoriatic Arthritis Enbrel Is Indicated For Reducing Signs And Symptoms, Inhibiting The Progression Of Structural Damage Of Active Arthritis, And Improving Physical Function In Patients With Psoriatic Arthritis (psa). Enbrel Can Be Used With Or Without Methotrexate. 1.4 Ankylosing Spondylitis Enbrel Is Indicated For Reducing Signs And Symptoms In Patients With Active Ankylosing Spondylitis (as). 1.5 Plaque Psoriasis Enbrel Is Indicated For The Treatment Of Patients 4 Years Or Older With Chronic Moderate To Severe Plaque Psoriasis (pso) Who Are Candidates For Systemic Therapy Or Phototherapy.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Etanercept

Comments